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Objective: This study aimed to investigate the expression of the MSH2 DNA repair protein in head and neck squamous cell carcinoma (HNSCC) in order to analyze its association 
with clinicopathologic factors and overall survival of patients. Material and Methods: Clinical 
data and primary lesions of HNSSC were collected from 55 patients who underwent surgical 
resection with postoperative radiotherapy in Montes Claros, state of Minas Gerais, Brazil, 
between 2000 and 2008. Immunohistochemical reactions were performed to analyze 
MSH2 protein expression. Results: Bivariate analysis showed no significant correlation or 
association between MSH2 expression and clinicopathologic parameters by Mann-Whitney 
and Kruskal-Wallis tests. Patients with locoregional metastatic disease (OR=4.949, p≤0.001) 
and lower MSH2 immunohistochemical expressions (OR=2.943, p=0.032) presented poorer 
survival for HNSCC by Cox regression models. Conclusions: Our data demonstrated that 
lower MSH2 expression might contribute to a higher clinic aggressiveness of HNSCC by 
promoting an unfavorable outcome.
Keywords: Squamous cell carcinoma. DNA repair. MutS homolog 2 protein. 
Immunohistochemistry. Prognosis.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) 
is the most prevalent malignant neoplasm arising 
from the epithelial lining of the upper aerodigestive 
tract mucosa. It represents the 6th most common 
type of human cancer, and it is responsible for high 
death rates worldwide every year4,10. A plethora of 
sociodemographic, economic, and cultural factors 
are associated with the development of HNSCC, 
along with a background of molecular disturbances, 
both genetic and epigenetic, that influence the 
course and incidence of the disease1,8.
Mismatch repair (MMR) is responsible for 
mismatch base substitution and insertion-deletion 
mismatches generated during DNA replication. 
MMR also recognizes DNA damage formed by 
chemical compounds, such as alkylating agents. 
Inactivation of MMR genes and proteins can have 
profound biological consequences on cells such 
as an increased tendency of mutations in genes 
associated with maintenance and replication of 
genome14,20. A crucial part of this system is the 
MutS-homologue 2 (MSH2) gene, which is located 
at chromosome 2p22. MSH2 protein recognizes 
DNA mismatches by forming two functional 
heterodimers: MSH2-MSH6, and MSH2-MSH3. 
MSH2-MSH6 recognizes single-base mismatches 
and short insertion-deletion loops, and MSH2-MSH3 
which recognizes larger loops that occur during DNA 
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replication6,22.
Disorders in MMR results in microsatellite 
instability and the accumulation of mutations 
in proto-oncogenes or tumor suppressor genes 
which can lead to cancer development. Moreover, 
it has been observed that tumors with loss of 
MSH2 expression showed increased frequency of 
microsatellite instability23,24. This mechanism is 
characterized by small insertions or deletions within 
short tandem repeats in tumor DNA when compared 
with the corresponding normal DNA2. Tumors 
with MSI frequently show somatic alterations in 
repetitive DNA tracts of several genes involved in 
cell growth control, apoptosis, and DNA repair7,27,29.
Molecular disturbances in the repair mechanisms 
mediated by the MSH2 repair confer susceptibility 
on tumor cells to present somatic mutations 
throughout the genome. Furthermore, these 
alterations in expression of MSH2 have been 
associated with chromosomal or genomic instability 
which, at a molecular level, might predispose to 
HNSCC7,29. However, little is known about the role 
of MSH2 in prognostic of patients with HNSCC. The 
aim of this study was to investigate the expression 
of the MSH2 DNA repair protein in the carcinoma 
cells of HNSCC in order to analyze its association 
with clinicopathologic factors and overall survival 
of patients.
MATERIAL AND METhODS
Tissue specimens, patients, and ethical 
aspects
This retrospective analytical study was performed 
using archived tissue blocks from 55 surgically 
resected primary lesions from patients with HNSCC, 
confirmed by morphological analysis (male-to-
female ratio, 4.5:1; mean age, 61.2±12.9 years). 
All selected patients underwent surgical resection 
followed by postoperative radiotherapy. Clinical 
and outcome data from the HNSCC patients were 
obtained from the health records at reference 
centers for diagnosis and oncology treatment 
between 2000 and 2008 in Montes Claros, Minas 
Gerais, Brazil. ethical approval for this study was 
obtained from the relevant local ethics committees 
(Unimontes: 1564/2008).
Clinical staging
HNSCC tumors were classified according to 
the International Union Against Cancer TNM 
Classification of Malignant Tumors and the 
International Classification of Diseases for 
Oncology26. TNM staging resulted in the following 
distribution: stage I, 1 patient (1.8%); stage II, 4 
(7.3%); stage III, 23 (41.8%); and stage IV, 27 
(49.1%). The anatomical site of HNSCC lesions 
were distributed in oral cavity (n=19, 34.5%), 
oropharynx (n=23, 41,8%), hypopharynx (n=5, 
9.1%), and larynx (n=8, 14.5%). The lesions 
located in the oral cavity were considered as the 
anterior group and those located in the oropharynx-
hypopharynx-larynx as the posterior group for 
characterization of the anatomical site variable. 
Clinical factors were classified as follows: local 
recurrence: absence (n=38, 69.1%) and presence 
(n=17, 30.9%); tumor size: small lesions (T1/
T2, n=8, 14.5%) and large lesions (T3/T4, n=47, 
85.5%); locoregional metastasis: absent (n=24, 
43.6%) and present (n=31, 56.4%); distant 
metastasis: absent (n=51, 92.7%) and present 
(n=4, 2.3%).
Morphological staging
Paraffin-embedded archival tissue from 
primary HNSCC were cut in 5 μm thick sections, 
deparaffinized, and stained with hematoxylin and 
eosin. Only specimens with clear morphological 
evidence of tumor infiltration into the connective 
tissue were included. Morphological analysis was 
carried out by an oral pathologist (AMB de Paula) 
with no prior knowledge of the epidemiological or 
clinical data of the selected patients. Kappa statistic 
was used to assess intra-examiner reproducibility 
(AMB de Paula) relating to morphological grades 
of OSCC. Kappa test revealed good concordance 
for OSCC groups (WHO, 1995, k=0.877, p=0.000; 
Invasive Front Grading, k=0.492, p=0.024). All 
HNSCC samples were reviewed and graded using 
the cell differentiation degrees of the World Health 
Organization (WHO)21 and Invasive Front Grading 
(IFG)3. In these morphological grading systems, 
high malignancy scores are considered to be 
representative of a poorly differentiated tumor 
and exhibited evidence of morphological severity, 
such as absence or decreased keratinization, high 
cell dissociation, and diffuse infiltrative pattern. 
The lesions were morphologically classified as 
follows: well/moderately differentiated (I/II) vs. 
poorly differentiated (III) (WHO grading) and 
accordingly with IFG, the grading was classified 
into three groups: F1 (4-8 points), F2 (9-12 points) 
and F3 (13-16 points). Higher scores for IFG have 
been associated with greater clinicopathologic 
aggressiveness of malignant disease.
Immunohistochemical (IhC) analysis
HNSCC sections were deparaffinized in xylene 
and rehydrated in a series of descending ethanol 
concentrations. Thereafter, the sections were 
treated in a pressure boiler with TRIS eDTA 
(pH=7.4) for 5 min at 121°C. The sections were 
submitted to 5 min blocking with endogenous 
peroxidase and 0.03% hydrogen peroxide in 100% 
ethanol. After washing with 10 mM phosphate-
buffered saline (PBS) (pH=7.6) for 5 min, the 
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sections were incubated with Protein Block Serum-
free (Dako, California, USA) prior to incubation 
with primary antibodies overnight at 4°C. The 
primary antibody used was mouse monoclonal 
anti-MSH2 (dilution 1:80; clone 25D12, Abcam, 
Cambridge, USA). The sections were thereafter 
incubated with streptavidin-biotin labeled antibody 
(LSAB-Kit Plus Peroxidase; Dako, California, USA) 
for 30 min. Tissues were stained for 5 min with 
3,3′-diaminobenzidine tetrahydrochloride freshly 
prepared in 10 mM PBS containing 0.1% hydrogen 
peroxide and then counterstained with Mayer’s 
hematoxylin and mounted in Permount (Fisher 
Scientific, New Jersey, USA). Positive control 
was applied according to the manufacturer’s 
instructions, and negative controls were employed 
by replacing the primary antibody with Universal 
Negative Control (Dako, California, USA).
Counting of immunostained samples
Samples were evaluated by one independent 
observer using an optical Olympus® BH2 microscope 
(model: CX31; RTSF, Miami, USA), with 10x ocular 
and 40x objective lenses and an ocular lattice 
(area: 0.092 mm2). Counting of 12 fields in the 
invasive front of HNSCC was performed to calculate 
Figure 1- Immunohistochemical expression of MSH2 repair protein in healthy oral mucosa and carcinoma cells of the 
invasive front of head and neck squamous cell carcinoma (HNSCC). A: Low immunohistochemical expression in basal 
layer of oral healthy epithelium. B/C: High immunohistochemical expression cases of HNSCC. Slides were stained with 
diaminobenzidine and counterstained with Mayer’s haematoxylin
DNA Repair Proteins Immunoexpression
Covariates MSH2
Anatomical Site Mean±SD p
Anterior (n=20) 80.77±22.10 0.523
Posterior (n=35) 81.92 ± 21.49
Recurrence
Absent (n=38) 81.15±20.17 0.449
Present (n=17) 82.28±24.90
Tumor Size
Small (n=8) 89.85±8.25 0.317
Large (n=47) 80.08±22.78
Locorregional Metastasis
Absent (n=24) 79.90±26.56 0.946
Present (n=31) 82.74±16.99
WHO Grading
Well/Moderate differentiated (n=39) 85.21±14.61 0.339
Poorly differentiated (n=16) 72.45±31.66
IFG
4-8 (n=6) 87.95±16.12 0.509
9-12 (n=22) 77.85±25.36
13-16 (n=27) 83.04±19.20
Table 1- Bivariate analysis between the clinicopathologic covariates and the mean values of MSH2 immunohistochemical 
expression in the head and neck squamous cell carcinoma samples
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the percentage of positive carcinoma cells. Only 
carcinoma cells with a distinct brown staining of 
the nucleus were considered positive (Figure 1). 
For statistical reasons, in order to analyze the 
overall survival of patients and clinicopathologic 
parameters, the mean values of the staining 
percentages of MSH2 were used in study.
Statistical analysis
All data were transferred to SPSS 17.0 software 
(SPSS Inc., Chicago, Illinois, USA) and subjected 
to specific tests. The Kolmogorov-Smirnov test 
was used to determine whether the distribution 
of continuous variable was normal. The analysis 
of MSH2 protein expression in tissues assumed 
non-parametrical distribution, and comparisons 
between groups were performed using the Mann-
Whitney test. The prognostic significance of all 
covariates (clinicopathologic factors and MSH2 
protein immunoexpression) for overall survival data 
were evaluated using Kaplan-Meyer test and Cox 
regression models. Associations among variables 
were considered significant when the confidence 
level was >95% (p<0.05).
RESULTS
The immunohistochemical evaluation showed 
that MHS2 protein was detected only in the nucleus 
of malignant epithelial cells. In all HNSCC samples 
investigated, it was noted that the invasive fronts 
exhibited a higher number of cancer cells with a 
strong nuclear signal (Figure 1). Immunopositivity 
for MSH2 protein was noted in 96.4% of samples 
(mean±s.d. and median: 81.5%±21.5% and 90%, 
respectively). Table 1 shows bivariate comparisons 
between the clinicopathologic covariates and 
the mean values of MSH2 immunohistochemical 
expression. No clinicopathologic covariates 
exhibited a significant association with expression 
of the MSH2 protein.
In overall survival analysis, HNSCC patients 
Covariates 95% CI
OR Lower Upper p
Anatomical Site
Anterior Referent
Posterior 2.120 0.216 1.029 0.059
Locoregional Metastasis
No Referent
Yes 4.949 2.045 11.979 0.000*
MSH2 Expression
High Referent
Low 2.943 1.212 7.142 0.032*
Table 2- Overall survival for the head and neck squamous cell carcinoma patients of this study using Cox regression 
analysis
Figure 2- Overall survival analysis in head and neck squamous cell carcinoma patients using Kaplan-Meier survival curves 
after 2704 days, according to locoregional metastatic disease (A) and MSH2 protein expression (B). Differences between 
groups were evaluated by the log-rank test
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were followed for a period from 116 to 2704 days 
(mean: 929.1±622.8 days and median: 749 days). 
It was noted that 22 patients (40%) were alive and 
33 patients (60%) died from disease at the end of 
the period. Patients who died without evidence of 
recurrence/metastasis were considered censored 
by the last clinical evaluation. In the bivariate 
analysis (Kaplan-Meyer curves), the covariates 
locoregional metastatic disease (p=0.002) and low 
expression of MSH2 protein (p=0.025) exhibited 
a significant association with poor overall survival 
(Figure 2). Subsequently, using Cox’s regression 
multivariate models, significant differences were 
again noted when we tested the relationship 
between the covariates of locoregional metastasis 
(OR=4.949; CI 95%=2.045-11.979; p<0.001) 
and low expression of MSH2 (OR=2.943; CI 
95%=1.212-7.142; p=0.032), with a worse overall 
survival (Table 2).
DISCUSSION
The mismatch repair pathway is responsible 
for correcting base substitution mismatches and 
insertion-deletion mismatches generated during 
DNA replication or recognizing genetic damage14,20. 
MSH2 is the most abundantly expressed mismatch 
repair protein and its inactivation can have 
profound pathologic consequences on DNA, 
particularly in microsatellite sequences, rendering 
them dysfunctional due to instability. Importantly, 
the presence of this type of DNA damage is 
considered to be an established biomarker for loss 
of mismatch repair activities in cancer cells6,22. 
Notably, few data are available about the role of 
MSH2 gene status or tissue expression for both 
upper aerodigestive tract mucosa carcinogenesis 
and for the progression of HNSCC7,27,29. In this 
present study, similar with findings of other human 
cancers studies that showed a low frequency of 
MSH2 immunonegativity (microsatellite instability-
high phenotype) in different human cancers5,18,19, 
we noted a down-regulation of MHS2 protein 
expression in approximately 9% of HNSCC samples. 
Different mechanisms may lead to loss of MSH2 
protein expression, such as mutation in the MSH2 
gene itself that leads to a lack of expression of 
this protein or to the expression of a truncated, 
non-functional form9. Another mechanism could be 
MSH2 gene promoter hypermethylation which can 
result in its transcriptional silencing15.
 HNSCC patients frequently exhibit low rates of 
overall and disease-free survival4,10. In the present 
study, bivariate and multivariate analysis showed 
that HNSCC patients whose malignancy exhibited 
low protein expression of MSH2 and locoregional 
metastasis had a worse overall survival. Reduced 
MSH2 protein expression has also been shown to 
be of unfavorable prognostic value for prostate 
cancer30, soft tissue sarcoma28, and biliary tract 
carcinoma11. Unfortunately, in a variety of human 
cancers, data on the prognosis of down-regulation 
of MSH2 expression are still contradictory5,12,13,17,19,25. 
Taking into account HNSCC7, the prognostic value of 
loss of MSH2 protein expression is unclear, mainly 
because the few existing studies have presented an 
insufficient number of patients or perhaps because 
squamous cell carcinomas from the different 
anatomic sites of the upper aerodigestive tract seem 
to exhibit distinct risk factors (environmental and 
genetic/epigenetic factors), clinical presentations, 
and outcomes, which may influence the evaluation 
of potential prognostic markers. According to 
our findings, the down-regulation of MSH2 and 
consequent loss of mismatch repair activities in 
transformed cells could promote an increased 
tendency of the genome to acquire mutations in 
genes associated with maintenance and replication 
of the genome, inducing in cancer cells a more 
aggressive phenotype and resulting in a worse 
prognosis for HNSCC patients. Finally, we confirmed 
that HNSCC individuals presenting with locoregional 
metastatic disease also had a poor overall survival. 
This finding is consistent with fundamental concepts 
that lymph node status is the most important 
predictor of survival16, which is confirmed in our 
population of head and neck carcinoma patients.
Our study, however, has a number of limitations 
such as the small sample size and the typical 
difficulties of cross-sectional study design to 
establish causal inference. Unfortunately, it was 
not possible to investigate the participation of 
other genetic or epigenetic disturbances that 
could interfere with the expression and functional 
activity of MSH2. Otherwise, our findings show 
that the immunohistochemical expression of MSH2 
protein seems to contribute to the identification of 
patients who had a poor prognosis. These findings 
might be useful for selecting HNSCC patients for 
adjuvant radiotherapy/chemotherapy protocols. 
However, future large clinical and molecular studies 
are needed to foster a better understanding about 
the reliability of MSH2 protein as an indicator of 
biological behavior of HNSCC or as a potential 
molecular therapeutic target for this type of cancer.
CONCLUSION
In conclusion, this study showed that reduced 
MSH2 expression in HNSCC tissues was associated 
with poor overall survival for patients. This low 
expression of MSH2 might contribute to a higher 
genomic instability and an increase in molecular 
disturbances resulting in a worse prognosis for 
patients.
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